Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study
Evaluation of the efficacy and safety of adding rituximab after failure of target immunotherapy in the Posterior treatment of advanced hepatocellular carcinoma
Advanced Hepatocellular Carcinoma
DRUG: Rituximab+PD-1 or PD-L1 inhibitors+targeted therapy
ORR, mRESIST, from the date of enrollment to death from any cause. (assessed up to 12 months）
PFS, mRESIST, from the date of enrollment to death from any cause. (assessed up to 12 months）|OS, mRESIST, from the date of enrollment to death from any cause. (assessed up to 12 months）|DoR, mRESIST, from the date of enrollment to death from any cause. (assessed up to 12 months）|DCR, mRESIST, from the date of enrollment to death from any cause. (assessed up to 12 months）
Evaluation of the efficacy and safety of adding rituximab after failure of target immunotherapy in the Posterior treatment of advanced hepatocellular carcinoma